All questions
Safety: Mounjaro (tirzepatide) in type 2 diabetes 9 questions · 3 sources
Safety questions that apply to every indication of Mounjaro are on Mounjaro (tirzepatide), all indications: Safety .
Side effects What are the long-term side effects of Mounjaro over 104 weeks (SURPASS-EARLY)? Applies to Adults with type 2 diabetes diagnosed within 0 to 4 years and inadequately controlled on metformin alone (SURPASS-EARLY)
Note: The adverse event values are from the table description on the clinical data page, whose opening sentence describes the hypoglycemia table; the values match the visible Common Adverse Events Occurring in ≥5% of Patients table. Each percentage is the incidence of the event through week 104. SURPASS-EARLY is not described in the Prescribing Information.
What are the most common side effects of Mounjaro? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Note: Table 1 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order (% of patients).
Mounjaro nausea and stomach side effects: how common are they? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).” (opens the source at this quote in a new tab) Copy Flag
Do Mounjaro stomach side effects like nausea go away over time? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
How can Mounjaro nausea and stomach side effects be reduced? Note: The eating suggestions are an endocrinologist's counseling advice for pediatric patients in the SURPASS-PEDS video on the pediatric page of the Mounjaro HCP site; they do not appear in the Prescribing Information.
Does Mounjaro cause low blood sugar, especially with insulin or a sulfonylurea? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea [see Clinical Studies (14)]. In an adult clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level <54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.” (opens the source at this quote in a new tab) Copy Flag
Note: Table 2 columns are placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, in that order.
What are the side effects of Mounjaro in children? Applies to Glycemic control as an adjunct to diet and exercise in pediatric patients 10 years of age and older with type 2 diabetes mellitus
“The incidences of adverse reactions reported in pediatric patients treated with MOUNJARO 5 mg and 10 mg subcutaneously once-weekly were consistent with those described above for adult patients with type 2 diabetes mellitus with the exception of a higher incidence of vomiting, abdominal pain, and hypoglycemia. During the 30-week placebo-controlled period of the study, vomiting occurred in 3%, 16%, and 12% of patients and abdominal pain occurred in 9%, 22%, and 15% of patients treated with placebo, MOUNJARO 5 mg, and 10 mg, respectively.” (opens the source at this quote in a new tab) Copy Flag
“A table that shows the adverse events in pediatric patients in the Mounjaro 5 mg (n=32), Mounjaro 10 mg (n=33), pooled Mounjaro (5 mg and 10 mg) (n=65), or placebo (n=34) groups. Percentages reflect the number of patients who reported at least 1 occurrence of the adverse event in the Mounjaro 5 mg group, Mounjaro 10 mg group, pooled Mounjaro (5 mg and 10 mg) group, and placebo group, respectively. Diarrhea: 8 (25%), 8 (24%), 16 (25%), and 2 (6%). Nausea: 7 (22%), 6 (18%), 13 (20%), and 3 (9%). Vomiting: 5 (16%), 4 (12%), 9 (14%), and 1 (3%). Upper abdominal pain: 2 (6%), 4 (12%), 6 (9%), and 3 (9%). Abdominal pain: 5 (16%), 1 (3%), 6 (9%), and 1 (3%). Dyspepsia: 2 (6%), 4 (12%), 6 (9%), and 0. Headache: 2 (6%), 3 (9%), 5 (8%), and 1 (3%). Oropharyngeal pain: 3 (9%), 1 (3%), 4 (6%), and 2 (6%). Cough: 3 (9%), 1 (3%), 4 (6%), and 1 (3%). Hyperglycemia: 0, 0, 0, and 5 (15%). Nasopharyngitis: 1 (3%), 2 (6%), 3 (5%), and 2 (6%). Decreased appetite: 0, 4 (12%), 4 (6%), and 0. Anxiety: 1 (3%), 2 (6%), 3 (5%), and 0. Gastroenteritis: 0, 0, 0, and 2 (6%). Injection site reaction: 0, 2 (6%), 2 (3%), and 0. Tonsillitis: 2 (6%), 0, 2 (3%), and 0.” (opens the source at this quote in a new tab) Copy Flag
On the page, select: Table description
Note: Table 3 columns are placebo, MOUNJARO 5 mg, and 10 mg, in that order. The visible SURPASS-PEDS adverse events table on the pediatric page labels the pooled group n=33 and gives pooled vomiting as 13 (20%) and placebo vomiting as 3 (9%); its table description gives n=65, 9 (14%), and 1 (3%). The label combines abdominal pain and upper abdominal pain, which the site lists separately.
How common are injection site reactions with Mounjaro? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Does Mounjaro increase heart rate? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“In the pool of placebo-controlled trials in adults, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.” (opens the source at this quote in a new tab) Copy Flag